1130 - Ensovibep antiviral activity in ambulatory patients with COVID-19 is independent of baseline anti-SARS-CoV-2 antibodies and exhibits minimal selective pressure – Results from the placebo-controlled EMPATHY trial

Friday, October 21, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

The ePoster content is available to users who are logged in.<br><br>Please click the login button at the top right corner and then come back here to use this button.

Presenting Author(s)

Luis Abrishamian, MD

Principal Investigator
South Bay Clinical Research Institute, Redondo Beach, CA, USA
Redonda Beach, California, United States

Co-Author(s)

MB

Marc Bonten, MD, PhD

Julius Center for Health Sciences and Primary Care, University Medical Center
Utrecht, Utrecht, Netherlands
RC

Richa Chandra, MD

Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
East Hanover, New Jersey, United States
DS

Damodaran Solai Elango, MD

Novartis Healthcare Pvt Ltd, Hyderabad, India
Hyderabad, Telangana, India
PF

Pierre Fustier, PhD

Molecular Partners AG, Zurich-Schlieren, Switzerland
Zurich-Schlieren, Zurich, Switzerland
KG

Kinfemichael Gedif, PhD

Novartis Pharmaceuticals Corporation, Fort Worth, TX, USA
Fort Worth, Texas, United States
SG

Susana Goncalves, MD

Novartis Pharma AG, Basel, Switzerland
Basel, Basel-Stadt, Switzerland
AI

Awawu Igbinadolor, MD

Monroe Biomedical Research, Monroe, NC, USA
Monroe, North Carolina, United States
JK

Jeff Kingsley, DO, MBA, CPI, FACRP

Centricity Research, Columbus, GA, USA
Columbus, Georgia, United States
CK

Charles G. Knutson, PhD

Novartis Institutes for BioMedical Research, Cambridge, MA, USA
Cambridge, Massachusetts, United States
PK

Petra Kukkaro, PhD

Novartis Pharma AG, Basel, Switzerland
Basel, Basel-Stadt, Switzerland
NK

Nagalingeswaran Kumarasamy, MD

VHS Infectious Diseases Medical Centre, Chennai Antiviral Research and Treatment Clinical Research Site, Chennai, India
Chennai, Tamil Nadu, India
PL

Philippe Legenne, MD

Molecular Partners AG, Zurich-Schlieren, Switzerland
Zurich-Schlieren, Zurich, Switzerland
MM

Martha Mekebeb-Reuter, MD

Excellentis Clinical Trial Consultants, George, South Africa
George, Western Cape, South Africa
KR

Krishnan Ramanathan, MD

Novartis Pharma AG, Basel, Switzerland
Basel, Basel-Stadt, Switzerland
ER

Evgeniya Reshetnyak, PhD

Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
East Hanover, New Jersey, United States
MR

Michael Robinson, PhD

Novartis Institute for Tropical Disease (NITD), Emeryville, CA, USA
Emeryville, California, United States
JR

Jennifer Rosa, MD

Clinresco Centres, Gauteng, South Africa
Gauteng, Gauteng, South Africa
MS

Marianne Soergel, MD

Molecular Partners AG, Zurich-Schlieren, Switzerland
Zurich-Schlieren, Zurich, Switzerland
VS

Vaia Stavropoulou, PhD

Molecular Partners AG, Zurich-Schlieren, Switzerland
Zurich-Schlieren, Zurich, Switzerland
NS

Nina Stojcheva, PhD

Molecular Partners AG, Zurich-Schlieren, Switzerland
Zurich-Schlieren, Zurich, Switzerland
MS

Michael T. Stumpp, PhD

Molecular Partners AG, Zurich-Schlieren, Switzerland
Zurich-Schlieren, Zurich, Switzerland
AT

Andreas Tietz, MD

Novartis Pharma AG, Basel, Switzerland
Basel, Basel-Stadt, Switzerland
XZ

Xiaojun Zhao, PhD

Novartis Institutes for BioMedical Research, Cambridge, MA, USA
Cambridge, Massachusetts, United States
ZZ

Zhaojie Zhang, PhD

Novartis Institutes for BioMedical Research, Cambridge, MA, USA
Cambridge, Massachusetts, United States